PAREXEL TECHNOLOGY ALLIANCE ENHANCES CLINICAL SUPPLY CHAIN FORECASTING AND MANAGEMENT
BOSTON, MA, February 20, 2007 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced an alliance between Perceptive Informatics, a PAREXEL company, and Tourtellotte Solutions, a leading provider of supply chain simulation technology, to enhance clinical supply chain forecasting and management for bio/pharmaceutical companies.
This technology alliance brings together the Perceptive Voice™ Interactive Voice Response System (IVRS) and Tourtellotte Solutions’ tcVisualize™ software, enabling bio/pharmaceutical companies to easily and accurately predict and manage their clinical study supply chain requirements. The Perceptive Voice IVRS offers clinical trial supply chain management capabilities, which allow study sponsors to monitor the drug supply at each site and automatically reorder supplies based on patient enrollment. The tcVisualize software is a clinical supply chain modeling and forecasting application.
“Accurate supply chain predictions are essential in clinical trials as drug shortages or delays can have a significant impact on study outcomes. We believe clients will be able to gain more control over their supply chain while improving the quality, efficiency and cost-effectiveness of their clinical trials with this new solution,” said Todd Joron, Corporate Vice President and General Manager, Perceptive Informatics.
“This alliance signifies a major step forward in clinical supply chain planning and management. We expect that PAREXEL’s and Perceptive’s clients will be able to answer, with greater accuracy, critical supply questions whether making a specific inquiry during their global trial, reviewing its supply history, or forecasting outcomes,” said Ed Tourtellotte, President, Tourtellotte Solutions.
The Perceptive Voice IVRS and Tourtellotte’s tcVisualize software provide visual representations of the supply chain at any phase of a clinical trial to streamline supply chain management, accurately calculate supply needs, and show implications of various scenarios to keep trials running at maximum efficiency.
To supplement the technology offering Perceptive Informatics is leveraging its technology expertise to provide consulting services, which will help clients with supply planning and forecasting.
For more information visit www.perceptive.com.
About Tourtellotte Solutions
Tourtellotte Solutions is a global leader in custom and packaged supply-chain software for the pharmaceutical, retail, and consumer goods markets. Tourtellotte Solutions’ tcVisualize, a groundbreaking clinical supply-chain modeling and forecasting application for the pharmaceutical industry, is used by several of the largest pharmaceutical companies. Tourtellotte Solutions is a privately-held company headquartered in Wayland, Massachusetts. For more information visit www.tourtellottesolutions.com.
About Perceptive Informatics, a PAREXEL Company
PAREXEL’s Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive’s portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT™ solution is Perceptive’s market-leading CTMS product with 25,000 users worldwide, and Perceptive’s INITIATOR™ trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 56 locations throughout 43 countries around the world, and has over 6,215 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2006 as filed with the SEC on February 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.